A Study of Brentuximab Vedotin and CHP in Frontline Treatment of PTCL With Less Than 10% CD30 Expression
Seagen Inc.
Seagen Inc.
Dana-Farber Cancer Institute
Daiichi Sankyo
Affimed GmbH
Ohio State University Comprehensive Cancer Center
Affimed GmbH
BeiGene
HUYABIO International, LLC.
AstraZeneca
Kura Oncology, Inc.
Kyowa Kirin Co., Ltd.
Northwestern University
University of Michigan Rogel Cancer Center
Solasia Pharma K.K.
University of Nebraska
Seagen Inc.
University of Nebraska
Weill Medical College of Cornell University
Eastern Cooperative Oncology Group
Karyopharm Therapeutics Inc
Mayo Clinic
Spectrum Pharmaceuticals, Inc
Eisai Inc.
University of California, San Francisco
Eisai Inc.
Celgene
Fred Hutchinson Cancer Center
Acrotech Biopharma Inc.
Fondazione Italiana Linfomi - ETS
Roswell Park Cancer Institute
University of Chicago
Wake Forest University Health Sciences
Fred Hutchinson Cancer Center
Fred Hutchinson Cancer Center
Fred Hutchinson Cancer Center
University of Washington
Fred Hutchinson Cancer Center
Fred Hutchinson Cancer Center
National Institutes of Health Clinical Center (CC)
National Cancer Institute (NCI)
Valerio Therapeutics
Yale University
M.D. Anderson Cancer Center